Search Drug, Disease, Toxicology, and more

Ask Watson

Search Micromedex drug information


Conversational Search:

Micromedex with Watson uses cognitive computing in the IBM cloud to gather search intent through conversation, provide specific clinical answers, and guide clinicians to relevant evidence.

How Micromedex with Watson Works:

Ask questions in a natural way, the way clinicians ask clinicians. The more specific the question, the more specific the answer. Examples:

  • What's the adult dose of lisinopril for hypertension?
  • What are approved uses for pristiq?
  • What are the adverse effects of digoxin?
  • Can cefazolin be given IV push?
  • How fast can Daptomycin be given?

Micromedex with Watson Understands:

Watson is in medical residency and can answer many drug information questions. The system learns from interaction with users and will be able to answer more sophisticated questions over time. For now, answers are limited to:

  • Drug Information (e.g. Drug Classes, Dosing, Administration, Medication Safety, Mechanism of Action, Pharmacokinetics, About)
  • Drug Interactions
  • IV Compatibility

Micromedex with Watson does NOT Understand:

  • In Depth Answers
  • NeoFax/Pediatrics, Toxicology, Disease, Lab, Alternative Medicine, Reproductive Risk
  • Third Party content (e.g. Martindale, Index Nominum)

Disclaimer:

IBM’s statements regarding its plans, directions, and intent are subject to change or withdrawal without notice at IBM’s sole discretion. Information regarding potential future products is intended to outline our general product direction and it should not be relied on in making a purchasing decision. The information mentioned regarding potential future products is not a commitment, promise, or legal obligation to deliver any material, code or functionality. Information about potential future products may not be incorporated into any contract. The development, release, and timing of any future features or functionality described for our products remains at our sole discretion.

Please enter a search term.
Latest News
  • Sevenfact(R) for Hemophilia
  • COVID-19 News
  • MDX COVID-19 Resources
  • FDA: Ranitidine Market Withdrawal
Latest News Close X

On April 1, 2020, the US FDA approved Sevenfact(R) (coagulation factor VIIa-jncw) IV injection indicated to treat and control bleeding episodes in adults and adolescents 12 years of age or older with hemophilia A or B with inhibitors. Sevenfact, which contains an active ingredient expressed in genetically engineered rabbits, demonstrated a significantly high proportion of successfully treated mild or severe bleeding episodes in clinical trials. It carries a boxed warning regarding the risk of thrombosis.

Prescribing information can be found at: https://www.fda.gov/media/136610/download.

The monograph for coagulation factor VIIa -jncw can be found at: http://www.micromedexsolutions.com/micromedex2/librarian/deeplinkaccess?source=deepLink&SearchTerm=coagulation+factor+VIIa-jncw.

Last modified: 04/07/2020 12:08:39 Full Article View Full Article.

FDA: COVID-19 and NSAIDs

On March 19, 2020, the US FDA addressed reports which raise concerns about the use of NSAIDs, particularly ibuprofen, in patients with Coronavirus 2019 (COVID-19). The FDA is currently not aware of scientific evidence establishing an association between ibuprofen and worsening COVID-19 symptoms. All prescription NSAID labels warn that "the pharmacological activity of NSAIDs in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections." Patients who use over-the-counter (OTC) or prescription drugs should take these medications in accordance with instructions on the label and as directed by their health care professional. The FDA is investigating this issue further and will communicate publicly when more information is available. For the full FDA statement, visit the following link: https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19.

HFSA/ACC/AHA: COVID-19 and Antihypertensives

On March 17, 2020, the HFSA/ACC/AHA issued a statement addressing the use of antihypertensives (ie, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or other renin angiotensin aldosterone system (RAAS) antagonists) in COVID-19 patients. Presently, there are no clinical data showing any benefits or risks with the use of antihypertensives in Coronavirus 2019 (COVID-19) patients with a history of cardiovascular (CV) disease. Therefore, healthcare clinicians should not initiate or discontinue any antihypertensive therapy in patients presenting with COVID-19 and underlying CV disease and should make individualized treatment decisions based on best practice standards. As further research data are available, the HFSA/ACC/AHA will update these recommendations as needed. For the full HFSA/ACC/AHA statement, visit the following link: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19

FDA Guidance

The US FDA is working with US Government partners, including Centers for Disease Control and Prevention (CDC), and international partners to address the coronavirus disease 2019 (COVID-19) outbreak. The FDA plays a critical role in protecting the US from threats including emerging infectious diseases. For continual updates and press releases, visit the following FDA website: https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/coronavirus-disease-2019-covid-19.

Last modified: 04/03/2020 22:09:18

IBM Micromedex(R) has the following resources to provide assistance during the COVID-19 crisis:

IBM Micromedex(R) and DynaMed(R) COVID-19 Resource Catalog

Drug Consults

  • Coronavirus Disease 2019 (COVID-19) Overview - Drug Consult with information on Coronavirus for clinicians: https://ibm.biz/Bdqiw5
  • Coronavirus Disease 2019 (COVID-19) and Oncology Patients - Drug Consult with information on reducing the risk of COVID-19 in oncology patients: https://ibm.biz/BdqY5U
  • Coronavirus Disease 2019 (COVID-19) - Pharmacologic Management of Adults in the ICU - Drug Consult with information on managing critically ill adults with COVID-19: https://ibm.biz/BdqY55
  • Coronavirus Disease 2019 (COVID-19) Investigational Therapies - Drug Consult with information on Coronavirus investigational therapies for clinicians: https://ibm.biz/BdqZ8m
  • Coronavirus Disease 2019 (COVID-19) and Antihypertensives - Drug Consult with information on the use of antihypertensives in patients with COVID-19: https://ibm.biz/BdqYcM
  • Coronavirus Disease 2019 (COVID-19) and NSAIDs - Drug Consult with information on the use of NSAIDs in patients with COVID-19 symptoms: https://ibm.biz/BdqYcv
  • Treatment of Hospital-Acquired and Ventilator-Associated Pneumonia - Drug Consult which provides treatment guidelines for this patient population: https://ibm.biz/Bdqiu9
  • Sepsis and Septic Shock in Adults - Drug Therapy and Sepsis and Septic Shock in Pediatric Patients - Drug Therapy - Drug Consults that provide treatment guidelines for sepsis in adults and pediatric patients: https://ibm.biz/Bdqiwq and https://ibm.biz/BdqiwS

Investigational Drug Monographs

The following are investigational drugs that are being researched for the treatment of COVID-19:

COVID-19 EUA Drug Monographs

The US FDA has granted Emergency Use Authorization (EUA) for the following drugs to be used to treat suspected or laboratory-confirmed Coronavirus (COVID-19) infection in hospitalized patients:

Last modified: 04/02/2020 16:32:43

On April 1, 2020, the US FDA requested the immediate removal of all prescription and over-the-counter (OTC) ranitidine products (Zantac(R) and generics) from the market. This is the most recent step in an ongoing investigation of the risk of N-nitrosodimethylamine (NDMA), a probable human carcinogen, being found in ranitidine products. The FDA has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of NDMA.

Therefore, the FDA is sending letters to all ranitidine manufacturers requesting withdrawal of ranitidine products from the market. The FDA is also advising consumers to stop taking any OTC ranitidine products, dispose of them properly, not buy more, and use other approved OTC products. Patients taking prescription ranitidine should speak with their healthcare professional about other treatment options before stopping the medicine, as there are multiple drugs approved for the same or similar uses as ranitidine that do not carry the same risks from NDMA.

Last modified: 04/01/2020 12:40:13 Full Article View Full Article.

You don't currently have a subscription that includes this content. Please contact us to find out more about our subscription options.

Contact Us